Research programme: tetracycline derivatives - Paratek Pharmaceuticals

Drug Profile

Research programme: tetracycline derivatives - Paratek Pharmaceuticals

Alternative Names: Multiple sclerosis therapy - Paratek; P 004292; Stroke therapy - Paratek

Latest Information Update: 07 May 2015

Price : $50

At a glance

  • Originator Paratek Pharmaceuticals
  • Class Tetracyclines
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Acne; Asthma; Bacterial infections; Clostridium infections; Inflammatory bowel diseases; Multiple sclerosis; Myocardial infarction; Spinal muscular atrophy; Stroke

Most Recent Events

  • 09 Mar 2014 No development reported - Preclinical for Acne in USA (PO)
  • 09 Mar 2014 No development reported - Preclinical for Bacterial infections in USA (PO)
  • 09 Mar 2014 No development reported - Preclinical for Clostridium infections in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top